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Amyotrophic lateral sclerosis (ALS) is an incurable neurodegenerative disease characterized by pro-
gressive loss of motor neurons, gliosis, neuroinﬂammation and oxidative stress. The aim of this study was
to evaluate the involvement of NADPH oxidases (NOX) in the oxidative damage and progression of ALS
neuropathology. We examined the pattern of NOX expression in spinal cords of patients and mouse
models of ALS and analyzed the impact of genetic deletion of the NOX1 and 2 isoforms as well as
pharmacological NOX inhibition in the SOD1G93A ALS mouse model.
A substantial (10–60 times) increase of NOX2 expression was detected in three etiologically different
ALS mouse models while up-regulation of some other NOX isoforms was model-speciﬁc. In human spinal
cord samples, high NOX2 expression was detected in microglia. In contrast to previous publications,
survival of SOD1G93A mice was not modiﬁed upon breeding with constitutive NOX1 and NOX2 deﬁcient
mice. As genetic deﬁciency of a single NOX isoform is not necessarily predictive of a pharmacological
intervention, we treated SOD1G93A mice with broad-spectrum NOX inhibitors perphenazine and thior-
idazine. Both compounds reached in vivo CNS concentrations compatible with NOX inhibition and
thioridazine signiﬁcantly decreased superoxide levels in the spinal cord of SOD1G93A mice in vivo. Yet,
neither perphenazine nor thioridazine prolonged survival. Thioridazine, but not perphenazine, dam-
pened the increase of microglia markers in SOD1G93A mice. Thioridazine induced an immediate and
temporary enhancement of motor performance (rotarod) but its precise mode of action needs further
investigation. Additional studies using speciﬁc NOX inhibitors will provide further evidence on the re-
levance of NOX as drug targets for ALS and other neurodegenerative disorders.
& 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Amyotrophic lateral sclerosis (ALS) is a disease leading to motor
neuron degeneration, paralysis and death usually within ﬁve years
following diagnosis. Currently there is no cure for ALS. New
therapies and identiﬁcation of novel pharmacological targets are
urgently needed. The etiology of the disease appears multiple, but
remains unclear for most cases. A strong neuroinﬂammation in the
brain stem and spinal cord parenchyma is believed to contribute to
ALS progression. At the pathological level, neuroinﬂammation is
characterized by the proliferation and activation of microglia and
astrocytes, accompanied by the invasion of the central nervous
system (CNS) parenchyma by inﬂammatory cells. Although neu-
roinﬂammation may be neuroprotective in some instances, ex-
cessive production of pro-inﬂammatory cytokines and reactive
oxygen species (ROS) is believed to contribute to disease pro-
gression [1].
ROS are important signaling molecules necessary for a range of
physiological processes. However, excessive production of ROS
causes damage of biomolecules interfering with their normal
functions and leading ultimately to cellular dysfunction or even
death. A major source of ROS in the CNS is the family of NADPH
oxidases (NOX) [2]. NOX are transmembrane proteins comprising
7 members (NOX1-NOX5, DUOX1 and DUOX2), each with a spe-
ciﬁc tissue distribution and activation mechanism [3]. NOX cata-
lyze the reduction of molecular oxygen to superoxide radical anion
(O2∙), which in turn can give rise to other ROS, such as hydrogen
peroxide (H2O2) and hypochlorous acid (HOCl) [4]. Recent studies
have shown that genetic deletion of NOX isoforms is neuropro-
tective in mouse models of Parkinson's disease [5], stroke [6], and
prion disease [7]. Previous studies have proposed NOX1 and NOX2
as potential drug targets since they contribute to disease pro-
gression in a mouse model of ALS [8,9]. Moreover, it was recently
shown that NOX2 activity in peripheral neutrophils of ALS patients
has a prognosis value for disease outcome as lower NOX2 activity
correlated with increased survival [9].
However, the therapeutic relevance of NOX inhibition remains
unclear as validated speciﬁc small molecule NOX inhibitors are
only emerging [10,11]. We have recently found that some N-sub-
stituted members of the phenothiazine family inhibit NOX iso-
forms 1–5 [12]. Phenothiazines have numerous pharmacological
properties [13], and are used in humans as antipsychotics and
antiemetics. Since they cross the blood-brain barrier (BBB), we
hypothesized that they may inhibit NOX activity in ALS spinal
cord, curb neuroinﬂammation and slow down the progression of
the disease. To test this hypothesis, we administered perphenazine
or thioridazine to SOD1G93A mice, a model of familial ALS, and
evaluated the effect on clinical symptoms and molecular markers
of the disease.2. Methods
2.1. Chemicals and reagents
Hank's buffered salt solution (HBSS), fetal bovine serum (FBS)
and Amplex Red were purchased from Invitrogen. Thioridazine
hydrochloride, perphenazine, penicillin, streptomycin, phorbol
myristate acetate (PMA), diphenylene iodonium chloride (DPI),
dimethyl sulfoxide, superoxide dismutase 1 bovine (Cu/Zn SOD1),
catalase and Tween-20 were purchased from Sigma Aldrich. 2-(4-
Iodophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetra-
zolium, monosodium salt (WST-1) was acquired from Dojindo
Molecular Technologies.2.2. RA2 Cells
The granulocyte macrophage colony-stimulating factor (GM-
CSF)-dependent Ra2 microglia cell line generated by spontaneous
immortalization of primary mouse microglia [14] was cultured in
minimal essential medium with 10% fetal calf serum, 8 ng/ml GM-
CSF, penicillin (100 U/ml) and streptomycin (100 mg/ml) at 37 °C
and 5% CO2. RA2 cells were plated in 96 well plates at a density of
10000 cells/well and treated with 5 mg/ml LPS (ALX-581-007-L002,
Enzo Life Sciences) 24 h after plating for additional 24 h.
2.3. ROS measurements in intact cells
Levels of H2O2 produced by intact cells were measured using
Amplex Red ﬂuorescence as described [15]. The concentration of
O2∙ was measured as absorbance change of 1 mM WST-1 at
440 nm [16]. Fluorescence and absorbance were measured in a
FluoSTAR OPTIMA, BMG labtech instrument at 37 °C. Under the
conditions of pre-treatment with LPS and stimulation with PMA,
macrophages produce peroxynitrite [17], which can generate
ﬂuorescence in the HRP/Amplex red system [18]. The signal
measured in microglial RA2 cells upon PMA stimulation is speciﬁc
for H2O2 and O2∙ as it is inhibited in a concentration-dependent
manner by catalase in Amplex assay and by SOD in WST1 assay
(Supplementary Fig 1).
2.4. Real-time quantitative polymerase chain reaction
RNA was extracted from mouse spinal cords (SOD1G93A mice),
total brain (TDP43 and FUS mice) or from RA2 cells using the
Qiagen RNeasy mini kit following the manufacturer's instructions.
RNA concentration was determined using Nanodrop. 500 ng was
used for cDNA synthesis using Takara PrimeScript RT reagent Kit
following manufacturer's instruction. Real-time PCR was per-
formed using SYBR green assay on a 7900HT SDS systems from ABI
at the Genomics Platform, National Center of Competence in Re-
search Frontiers in Genetics, Geneva. The efﬁciency of each primer
was veriﬁed with serial dilutions of cDNA. Relative expression le-
vels were calculated by normalization to geometric mean of the
two house-keeping genes HPRT and GAPDH, as described pre-
viously [19]. The highest normalized relative quantity was arbi-
trarily designated as a value of 1.0. Fold changes were calculated
from the quotient of means of these normalized quantities and
reported as 7SEM. Sequences of all primers used in this study are
provided in Supplementary Table 1. Threshold cycle (Ct) values for
NOX subunits corresponding to the intersection between an am-
pliﬁcation curve and a threshold line set at 0.20 by the software
are provided in Supplementary Table 2.
2.5. Thioridazine and perphenazine determination in brain
Perphenazine (3 mg/kg) or thioridazine (10 mg/kg) were ad-
ministered i.p. After a desired time period (30 min – 8 h) mice
were sacriﬁced by lethal injection of Nembutal and perfused with
0.9% saline solution intracardially for 5 min. Brains were dissected,
snap frozen in liquid nitrogen, and stored at 80°C. Brains were
weighted and homogenized in 2 ml of deionized water. The ﬁnal
volume was adjusted to 5 mL with water. To 500 mL of homo-
genate, 100 mL of desmethylclobazam-d5 (internal standard) at
10 ng/mL and 3 mL of hexane/ethyl acetate (50/50 mixture) were
added. Liquid-liquid extraction was performed by shaking samples
for 30 min. After centrifugation at 1000 g for 10 min, the super-
natant was removed, evaporated and the residue reconstituted in
200 mL of MeOH/water (1:1, v/v). Finally, 20 mL were injected onto
the HPLC system. Along with the unknown samples, QC and
standards samples, prepared using blank brain spiked with
Table 1
Basic characteristics of ALS and non-ALS control patients.
Patient no Gender Age at
death
(years)
Duration of
disease
(months)
Pathology
1 F 67 14 ALS
2 F 60 30 ALS
3 M 46 72 ALS
4 M 77 19 ALS
5 F 62 n. a. ALS
6 M 77 30 ALS
C1 M 72 – Atrial ﬁbrillation; leptome-
ningeal venous angioma of
the cervical spinal cord
C2 M 36 – Gliomatosis cerebri
C3 F 73 – Central pontine myelinolysis
n. a.¼not available
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tion range were processed. All experiments were performed using
an API 4000 triple quadrupole mass spectrometer (AB Sciex,
Concord, ON, Canada) controlled by Analyst 1.5.1 software. The
mass spectrometer was operated in the multiple reaction mon-
itoring (MRM) mode with positive electrospray ionization. The
MRM transitions were 371.1-126.1, 404.1-171.1 and 292.1-
249.8 with a dwell time of 50 ms for thioridazine, perphenazine
and IS (desmethylclobazam-d5), respectively. The instrument was
directly coupled to an Agilent series 1100 (Waldbronn, Germany)
LC system. Chromatography was performed on a Phenomenex
Kinetex C18 analytical column (50 mm2.1 mm, 2.6 μm; Tor-
rance, CA, USA) preceded by a pre-column with the same phase.
Flow rate was 0.5 mL/min using gradient elution conditions. The
method was fully validated before application to this study. The
concentration of drugs was normalized to brain tissue weight and
expressed in mg/ml brain tissue assuming a brain density of
1.04 g/mL [20]. The normalization to volume was needed for the
presentation of the IC50 values for phenothiaizine compounds (mg/
ml) on the same graph.
2.6. In vivo labelling with dihydroethidium (HE) and detection of
reactive species by LC/MS/MS
HE stock solution (25 mg/ml) was prepared on the day of the
experiment in argon-purged DMSO under an argon-enriched at-
mosphere and with protection from light. 7.5 ml of this solution
was mixed with 7.5 ml 0.9% NaCl and injected intraspinally into
SOD1G93A mice (110 days). After 30 min mice were anesthetized
with Nembutal and perfused intracardially for 5 min with 0.9%
saline. Spinal cord was dissected, snap frozen and stored at
80 °C. Products of HE oxidation were quantiﬁed using LC/MS/MS
analysis as described previously [21].
2.7. Western blotting
Protein extracts were prepared by lysing the spinal cord tissue
in the buffer containing: 50 mM Tris–HCl pH 7.4; 50 mM NaCl;
10 mM MgCl2; 1 mM EGTA; 1% Triton-X100; Protease inhibitors
(Roche). BioRad assay was used for protein quantiﬁcation. Equal
amount (30 mg) of protein was loaded for analysis. After transfer,
the membrane was blocked for 1 h at room temperature in PBS/
0.5% Tween-20 buffer containing 5% fat-free milk (blocking buffer).
The membrane was incubated at 4 °C overnight with gp91phox
antibody (BD Transduction Laboratories, BD611415; 1/500 diluted
in blocking buffer). After washing, the membrane was incubated
for 1 h at room temperature with horseradish peroxidase-con-
jugated secondary antibody (1/10,000 in blocking buffer). Un-
bound secondary antibody was washed off. ECL kit (GE Healthcare)
was used to detect the signal.
2.8. Immunohistochemistry
Mice were anesthetized with Nembutal (i.p) and perfused in-
tracardially with cold PBS followed by cold 4% paraformaldehyde
(Sigma Aldrich, Saint Louis, USA). Spinal cords were removed and
stored for 24 h in 4% paraformaldehyde. Lumbar sections were
embedded in parafﬁn, cut in 10-mm-thick sections, and mounted
on glass slides. Deparafﬁnization was performed by a gradient of
alcohols. In order to expose the epitopes, tissues were boiled in
citrate buffer (0.01 mol/L, pH¼6) for 15 min. Prior to addition of
antibodies, unspeciﬁc binding was prevented by incubation of
tissues in blocking solution (0.2% Triton-X, 10% fetal calf serum,
PBS) for 30 min. Incubation overnight was performed at 4 °C with
either rabbit polyclonal Iba1 (Wako, 1:500) or mouse monoclonal
glial ﬁbrillary acidic protein (GFAP; MAB360, Chemicon, 1:1000)diluted in buffer (0.2% Triton-X100, PBS). Tissues were incubated
with secondary antibodies Alexa Fluor (A21424 and A11034, In-
vitrogen, 1:1000) for 30 min, DAPI for 10 min and mounted with
FluorSave (Calbiochem, San Diego). For visualization of neurons,
tissues were deparafﬁnized, stained with 0.1% cresyl violet for
5 min, and then dehydrated by a gradient of alcohols. Technical
controls were performed for each experiment by omitting the ﬁrst
antibody and performing the other steps of the procedure (data
not shown). Motor neurons were counted manually in the anterior
horn of mouse spinal cord slices. The intensity of Iba1 and GFAP
staining was analyzed using ImageJ software.
2.9. Immunostaining in human tissues
2.9.1. Patients
Human tissue samples used in this study (Table 1) were ob-
tained from the archive of the Institute of Neuropathology, Uni-
versity Hospital Zurich (samples 4–6, C3) and from the archive of
the Laboratory of Neuropathology, Department of Neuroscience,
University of Turin (samples 1–3, C1–C2). Samples were irrever-
sibly anonymized, dated prior to the year 2005, processed and
analyzed according to the Swiss Medical-ethical guidelines and
recommendations (Senate of the Swiss Academy of Medical Sci-
ences, Basel, Switzerland, 23 May 2006).
2.9.2. Immunohistochemistry
NOX2 staining was performed as described in [7]. Brieﬂy, anti-
human NOX2 (1:250, Clone 48, Sanquin) antibody was applied to
sections after deparafﬁnization and antigen retrieval. Staining was
visualized using DAB (Sigma-Aldrich) and H2O2 (Sigma-Aldrich),
after incubation with a biotinylated secondary antibody (Vector
Laboratories) and the ABC complex solution (Vector laboratories).
Hematoxylin counterstain was subsequently performed. Quantiﬁ-
cation of NOX2 expression in spinal cord sections was performed
as described before [7] on regions of interest drawn on different
areas of spinal cord sections.
2.10. Animals used in the study
B6SJL-Tg(SOD1G93A)1Gur/J (Stock Number: 002726) [22] mice
were purchased from Jackson laboratory and kept in standard con-
ditions in the conventional animal facility of Centre Médical Uni-
versitaire of the University of Geneva with free access to food and
water. All experiments were approved by the local veterinary ofﬁce
and the Commission for Animal Experimentation of the Canton of
Geneva, Switzerland, authorization number 1005/3445/2-R.
To generate ALS mice deﬁcient for NOX2, B6SJL-Tg
(SOD1G93A)1Gur/J males were crossed with homozygous NOX2KO
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NOX2-deﬁcient males carrying the SOD1G93A transgene were
crossed to female non-carriers heterozygous for NOX2 deletion
(NOX2þ /). From this breeding, only the progeny carrying the
SOD1G93A transgene was used for survival analysis: for females
NOX2þ //SOD Tg and NOX2 //SOD Tg; for males NOX2þ /y/SOD
Tg andNOX2 /y/SOD Tg. Genotyping was performed following the
Jackson lab protocols for B6SJL-Tg(SOD1G93A)1Gur/J and NOX2KO
B6.129S6-Cybbtm1Din/J.
RNA samples were obtained from symptomatic TDP-43 [23]
and FUS [24] transgenic mice, in which broad CNS expression of
human TDP-43 or FUS cDNA that mimic the endogenous TDP-43
and FUS expression pattern. In these two models, TDP-43 [23] or
FUS/TLS [24] cDNAwere placed under the control of a mouse prion
promoter to achieve CNS expression patterns similar to those of
endogenous TDP-43 and FUS/TLS. Mice expressing human
TDP-43Q331K, but not wild type human TDP-43, develop age-de-
pendent loss of motor neurons by 12-month [21]. Heterozygous
FUS/TLSWT mice develop normally while the homozygous
FUS/TLSWT mice develop rapid and progressive neurological phe-
notypes leading to paralytic disease by 40 days of age (this new
mouse model will be described in details elsewhere).
2.11. SOD1G93A mice treatment
Litters were split to enable even distribution of parentage be-
tween the two comparison groups, and the groups were randomly
assigned to treatment or control. Thioridazine solution was pre-
pared in NaCl 0.9%. Perphenazine was solubilized in acidiﬁed 0.9%
saline solution containing 0.005% acetic acid. Drugs and corre-
sponding vehicles were administered in 250 mL intraperitoneally
(i.p.). Injections were started when mice reached 70 days of age,
before the obvious appearance of clinical symptoms. Animals were
observed daily, weighed twice weekly and their motor function
was assessed using a grid test and rotarod. Rotarod training was
performed over three days with one 5 min trial per day. The ro-
tarod (Ugo Basile 7650) was set to accelerate from 4 to 40 rpm
over 300 s. Latency to fall was recorded in seconds (s) for each
mouse. Motor tests were performed once a week in the afternoon.
The survival endpoint was the loss of the righting reﬂex, i.e., the
inability of the animals to right themselves within 30 s after being
laid on each side. Animals were euthanized with terminal an-
esthesia by Nembutal injection followed by intracardiac PBS per-
fusion prior to the collection of samples for protein and RNA ex-
traction. For immunohistochemistry, paraformaldehyde (4% in
PBS) was perfused prior to collection of samples.
2.12. Statistical analysis
Data were analysed using Graph-Pad Prism software 6.03.
Student's t-test was used for cell culture experiments; non-para-
metric Mann-Whitney test was used for the experiments per-
formed on animal samples; a one-way ANOVA for repeated mea-
sures with Bonferroni's Multiple Comparison Test post-hoc ana-
lysis was used for behaviour experiments; log-rank (Mantel-Cox)
Test was used for lifespan comparison of treated versus vehicle
SOD1G93A mice.3. Results
3.1. NOX2 and its subunits are strongly up-regulated in ALS spinal
cord in mice and humans
The expression levels of all six mouse NOX isoforms and their
subunits were measured by qPCR using RNA isolated from thespinal cord of wild-type (120 days) and SOD1G93A mice at early (90
days) and terminal stage of disease (120 days) (Fig. 1A). DUOX1
and DUOX2 were below detection level (data not shown), but all
other NOX isoforms were detected (Ct values are shown in Sup-
plementary table 2). NOX3 was increased at similar levels at 90
and 120 days. NOX1, its subunits Noxo1 and Noxa1 or NOX4 did
not show expression levels changes. Interestingly a subunit of
DUOX1, DUOXA1 was detected in the spinal cord and its expres-
sion correlated with the disease progression. Expression of NOX2
and the subunits p22phox, p47phox, p67phox, p40phox and rac1 was
signiﬁcantly increased concomitantly with disease progression
(Fig. 1A). Consistent with mRNA expression data, NOX2 protein
was strongly increased in spinal cord of SOD1G93A mice (120 days)
(Fig. 1B). NOX mRNA expression was also measured in the spinal
cord of two additional mouse models expressing ALS-causing
genes, TDP-43 [23] and FUS/TLS [24] (Fig. 1C, D; see the materials
and methods section for the description of these models). Simi-
larly to SOD1G93A mice, NOX2 expression was strongly increased in
the spinal cord of TDP-43Q331K, but not in TDP-43WT mice at 12
months, as well as in symptomatic homozygous FUS/TLSWT (40
days), but not in non-symptomatic heterozygous FUS/TLSWT mice.
However, while NOX4 expression was unaffected in the spinal cord
of SOD1G93A mice, NOX4 expression levels showed a trend to an
increase in the spinal cord of TDP-43Q331K (Fig. 1C) and signiﬁcant
increase in homozygous FUS/TLSWT (Fig. 1D) mice at the late stages
of disease. We were not able to detect NOX1 and NOX3 in the
spinal cord of these mice. SOD1G93A mice remain the best char-
acterized model of ALS with visible clinical symptoms
onset at about 90 days of age, progressive hind limb paralysis,
massive motor neuron death, microgliosis and mortality
at 120–140 days of age [22]. Therefore we used this animal model
in the subsequent experiments. In human tissue, strong NOX2
immunostaining in the spinal cord from ALS patients was ob-
served in cells with typical microglial morphology (Fig. 2). A trend
towards increased levels of NOX2 in different regions of the spinal
cord was observed in the patients as compared to non ALS
controls.
3.2. Genetic deletion of NOX1 and 2 isoforms does not affect survival
of SOD1G93A mice
To assess the impact of NOX1 and NOX2 on the progression of
neurodegeneration in ALS, we bred NOX1 and NOX2-deﬁcient
mice (normal life span) with SOD1G93A mice and evaluated their
survival. No signiﬁcant change in survival was observed in neither
mice deﬁcient in NOX1 (Suppl. Fig. 2) nor NOX2 (Fig. 3A, B) for
both genders when compared to wild-type ALS littermates. In-
terestingly, we observed that the B6 background increased survival
of the SOD1G93A male mice as previously shown by others [25,26].
Thus, the comparison between matched littermates is necessary to
evaluate the effects of NOX deletion. NOX2 deﬁciency did not have
an impact on the expression of neuronal (neuroﬁlament light
polypeptide, NEFL), microglial (Iba1, CD68) and astroglial markers
(GFAP) neither in males nor in females (Fig. 3C). No obvious dif-
ferences in morphology of activated microglia were detected in
NOX2 deﬁcient ALS mice (Suppl. Fig. 3).
Constitutive genetic ablation has limitations for validating the
relevance of NOX targeting in ALS as i) NOX activity may be in-
volved in neuronal development [2] and adaptive mechanisms
might develop to compensate NOX-dependent signaling; ii) pre-
sence of NOX may be protective at early stages of ALS [27], iii)
other NOX isoforms (e.g. NOX3, NOX4) might be involved in dis-
ease progression. Therefore, we also tested a pharmacological
approach in order to inhibit all NOX, starting the treatment at early
stage of disease (day 70).
Fig. 1. NOX isoforms and subunits are upregulated in mouse models of ALS. (A) Quantitative real-time PCR was performed on mRNA from spinal cord of SOD1G93A mice at
different stages of disease (90 and 120 days, n¼4 males) and for non-carrier littermates (120 days, n¼4, males) for all NOX isoforms. NOX2 and NOX3 levels were strikingly
increased and no change was observed for NOX1 and NOX4 levels while DUOX1 and DUOX2 levels were below detection level (data not shown). Consistent with NOX2
increase, the expression of subunits p22phox, p40phox, p47phox, p67phox and rac1 was increased already at early stage of disease, however the NOX1 and NOX3 subunits
Noxo1 and Noxa1 were unchanged. DUOXA1 levels were increased with the progression of the disease. (B) Representative image of a western blot experiment showing
detection of a 50 kDa NOX2-speciﬁc band in the spinal cord lysates of SOD1G93A mice (ﬁnal stage of disease), which is absent in NC mice (120 day) and SOD1G93A mice bred
with NOX2 deﬁcient mice (ﬁnal stage of disease). (C-D) Quantitative real-time PCR was performed also on mRNA from the spinal cord of two additional mouse models of
ALS: (C) Increase in mRNA for NOX2 was found in the spinal cord of TDP-43Q331K, but not in TDPWT mice at 12 months (n¼4, males and females), (D) Increased expression of
NOX2 and NOX4 was observed in the spinal cord of symptomatic homozygous FUS/TLSWT, but not in non-symptomatic heterozygous FUS/TLSWT mice at 40 days (n¼3, males
and females). NOX1 and NOX3 levels were below detection threshold in these two models. For A, C, and D the values are expressed as a fold-change of NC mice, columns
represent the mean7SEM. Asterisks indicate a signiﬁcant difference as determined by Mann-Whitney test (*po0.05).
T. Seredenina et al. / Free Radical Biology and Medicine 97 (2016) 95–108 993.3. N-substituted phenothiazine compounds inhibit NOX-derived
ROS generation by microglial cells
The two N-substituted phenothiazine compounds, perphena-
zine and thioridazine (Fig. 4A), were chosen based on previous
pharmacological characterization [12] for evaluation in an in vitromodel of microglia activation. Pretreatment of cultured mouse
microglial cells RA2 with 5 mg/mL LPS from Escherichia coli (Ser-
otype R515 (Re)) lead to activated microglial morphology and in-
creased expression of NOX2 (Fig. 4B) that was accompanied by an
increase in PMA-induced production of ROS (Fig. 4C-D, dark grey
versus light grey bars). To evaluate the effect of the two
Fig. 2. NOX2 staining in ALS patients and controls. (A) and (B) NOX2-immunolabled cross sections of spinal cord from patients with amyotrophic lateral sclerosis (Scale bar:
1 mm). (A’-A”’) and (B’-B”’) show higher magniﬁcation (indicated by boxes in A and B) of anterior horn (A’ and B’), lateral funiculus (A” and B”) and dorsal columns (A”’ and
B”’). (C) and (D) depict anterior horn (C) and lateral funiculus (D) areas from a control case (Scale bar: 100 mm). (E) Bar graphs representing mean 7 SEM for NOX2 protein
expression, quantiﬁed as the percentage of the surface occupied by the NOX2 staining over the total measured area in selected regions: anterior horn left (ah l), anterior horn
right (ah r), lateral funiculus (lf) and dorsal column (dc) of ALS and control (ctrs) patients (ALS, n¼6; ctrs n¼3). Each circle in (E) represents a measure for a separate case.
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different validated assays: the peroxidase-dependent Amplex Red
ﬂuorescent assay which measures H2O2, and the colorimetric WST-
1 assay, which measures O2∙ [16]. Both, perphenazine and
thioridazine signiﬁcantly inhibited generation of H2O2 and O2∙ in
this model (Fig. 4C, D). This indicated that the tested phenothia-
zines are able to diminish NOX2-derived ROS production by acti-
vated microglial cells, and they were further tested in vivo.
3.4. Pharmacokinetics of perphenazine and thioridazine in vivo
N-substituted phenothiazines are used in the clinic for CNS
applications for over 50 years and their bioavailability in brain is
well documented [28,29]. To ensure that concentrations of drug
sufﬁcient for NOX inhibition are obtained in the CNS, we ad-
ministered perphenazine (3 mg/kg) or thioridazine (10 mg/kg) i.p.
to wild type mice and measured the brain content of each drug
after 0.5, 1, 2, 4 and 8 h. The brain concentration of perphenazine
(Fig. 5A) and thioridazine (Fig. 5B) reached maximal level 2-4 h
post injection, and these concentrations were above the respective
IC50 values for NOX2 inhibition (3.970.7 mM for perphenazine and
2.270.2 mM for thioridazine in cellular assays [12]) at least for 8 h.
The doses could not be increased to avoid the undesired sedative
effect of these drugs.
3.5. Effect of thioridazine on spinal cord ROS generation in vivo
Increased expression of NOX2 leads to elevated oxidative
modiﬁcations in ALS spinal cords [8]. Here, we assessed the spe-
ciﬁc reactive species generated in ALS spinal cords and NOX-in-
hibitory activity of thioridazine in vivo. For this, we used a LC/MS/
MS detection system to differentiate the products of HE oxidation
in the spinal cord SOD1G93A mice. In preliminary experiments we
evaluated three different delivery routes for HE: i.p., i.v. and in-
traspinal injection. We noticed signiﬁcant rapid oxidation of the
probe in the plasma upon i.p. and i.v. injections (data not shown).
In order to measure the speciﬁc oxidative activity occurring in the
spinal cord parenchyma, we opted for direct intraspinal delivery of
the probe for subsequent experiments. Thioridazine, 15 mg/kg,
was administered to SOD1G93A mice i.p. 2 h prior to HE injection.The following HE oxidation products were detected and quantiﬁed
in spinal cords: 2-hydroxyethidium (2-OH-Eþ), the speciﬁc pro-
duct of the reaction of HE with O2∙ [30]; ethidium (Eþ) non-
speciﬁc product of HE oxidation; ethidium dimers (Eþdimer) [31]
and 2-chlorethidium (2-Cl-Eþ), a speciﬁc product formed from the
reaction of HE with hypochlorous acid (HOCl) [21]. Consistent with
an increase of oxidative stress in the ALS spinal cord, 2-OH-Eþ
(Fig. 5C) [30] and Eþ dimer (Fig. 5E), but not Eþ (Fig. 5D) were
increased in spinal cords of SOD1G93A mice during the clinical
stage of the disease (110 days) as compared to NC littermates. We
expressed these oxidation products relative to HE to account for
possible differences in the concentration of the probe between
animals. Indeed, standardization of results to HE improved the
standard deviation. No difference in 2-chloroethidium (2-Cl-Eþ)
(Fig. 5F), an indicator of myeloperoxidase activity was observed in
the spinal cord of SOD1G93A mice. Mice treated with thioridazine
had signiﬁcantly lower levels of HE-normalized 2-OH-Eþ , the
speciﬁc product of O2∙ - induced HE oxidation and the primary
product formed by NOX2- than vehicle-treated controls. This in-
dicated that thioridazine indeed decreased ROS generation in the
spinal cord of SOD1G93A mice, possibly through NOX2 inhibition
(Fig. 5C).
3.6. Effect of perphenazine and thioridazine on disease progression
and survival of SOD1G93A mice
To assess the efﬁcacy of phenothiazine compounds in vivo in a
mouse model of ALS perphenazine, thioridazine or their respective
vehicles were administered i.p. daily to SOD1G93A mice starting at
70 days of age until terminal stage. We started the treatment at
early stage of disease in order to target the switch of microglial
activation state from protective to inﬂammatory which coincides
with increased expression of NOX2 [27]. A summary of the ex-
perimental details is shown in Table 2.
Survival of SOD1G93A mice was evaluated following treatment
with perphenazine (Fig. 6A) or thioridazine (Fig. 7A). The average
survival values are shown in Table 2. None of the compounds
signiﬁcantly increased survival.
We assessed general progression of the disease by weight loss,
motor performance (rotarod test), and muscle strength (time mice
Fig. 3. Genetic ablation of NOX2 in SOD1G93A mice does not improve survival or neurochemical markers. Survival of SOD1G93A mice was compared to SOD1G93A-NOX2
knockout mice (A) Double transgenic SOD1G93A /NOX2 deﬁcient hemizygous (NOX2Y/ , blue) males were compared to SOD1G93A /WT littermates (NOX2Y/þ , purple) and
historical SOD1G93A males in the hybrid B6SJL background (black), (B) Double transgenic SOD1G93A /NOX2 deﬁcient homozygous (NOX2/ , red) females were compared to
SOD1G93A /heterozygous littermates (NOX2þ /-, green) and historical SOD1G93A females in the hybrid B6SJL background (black). Average survival and number of animals per
group are indicated, log-rank (Mantel-Cox) test. (C) mRNA levels of the NOX2 subunit p47phox and neuronal (NEFL), microglial (Iba1, CD68) and astrocyte (GFAP) markers
were assessed using qPCR in the spinal cord of SOD1G93A mice crossed with NOX2 KO mice (n¼6 males and n¼5 females) and compared to NOX2 WT littermates (n¼4
males and n¼4 females) and non-carriers (n¼4 males and n¼4 females). Expression values were normalized to geometric mean of two house-keeping genes (GAPDH and
HPRT) and expressed as a fold-change of SOD1G93A non-carrier mice (NC). Values are presented as mean7SEM. Mann-Whitney test, *po0.05, **po0.01, ***po0.001.
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SOD1G93A mice resulted in signiﬁcant improvement of body
weight (Fig. 6B), but only a non-signiﬁcant trend was seen in the
rotarod and grid tests (Fig. 6C, D). Thioridazine treatment had no
effect on weight loss of SOD1G93A mice (Fig. 7B). Motor function
was enhanced in the rotarod test immediately after the start of
treatment (Fig. 7C); however, the deterioration of rotarod perfor-
mance was comparable in thioridazine and vehicle treated mice.
Muscle strength was not improved as shown by the grid test
(Fig. 7D).
3.7. Characterization of molecular markers
We further evaluated molecular changes in the spinal cord of
SOD1G93A mice by qPCR and immunohistochemistry. Pharmaco-
logical inhibition of NOX2 did not produce a neuroprotective effect
as shown by levels of the neuroﬁlament light polypeptide (NEFL)
mRNA (Fig. 8A, B) and quantiﬁcation of motor neurons (Fig. 8C).
Perphenazine treatment resulted in a trend to an increased ex-
pression of mRNA for micro- and astroglial markers, with astatistically signiﬁcant increase of CD68 expression. However this
effect was not conﬁrmed by evaluation of immunostaining for
microglial marker Iba1. Surprisingly, perphenazine increased the
expression of NOX2 mRNA in the spinal cord of treated mice. On
the other hand, thioridazine signiﬁcantly decreased the expression
levels of microglial markers Iba1 and CD68; moreover, a similar
trend was observed in immunostaining for Iba1 in lumbar spinal
cords of SOD1G93A mice. Also, we observed a trend towards a de-
crease in expression of the astrocyte marker GFAP both at mRNA
and protein levels in these animals. Interestingly, none of the
evaluated markers showed a difference in NOX2-deﬁcient versus
control ALS mice (neither in males nor in females) (Fig. 3C), sug-
gesting that the observed effects of phenothiazine compounds are
pleiotropic.4. Discussion
Curbing oxidative stress via phagocyte NADPH oxidase (aka
gp91phox or NOX2) inhibition has been proposed as a strategy for
Fig. 4. Effect of perphenazine and thioridazine on ROS generation by microglial cells in vitro. (A) Chemical structures of the phenothiazines used in the study. (B) NOX2
mRNA expression is increased in RA2 cells upon treatment with LPS 5 mg/mL for 24 and 48 h (n¼3). Columns show means 7 SEM; asterisks indicate a signiﬁcant difference
from control (no LPS treatment) as determined by two-tailed unpaired Student's t-test (***po0.001). Tested compounds (10 mM) inhibit the production of (C) H2O2, Amplex
Red assay and (D) superoxide radical anion, WST1 assay in RA2 cells pretreated with 5 mg/mL LPS for 48 h and stimulated with PMA 100 nM. The values obtained from
4 independent experiments were normalized to the control (RA2 cells pre-treated with LPS and treated with DMSO and PMA, 100%) and are presented as mean7SEM.
Student's t-test, *po0.05, **po0.01, ***po0.001. Per – perphenazine, Thio – thioridazine, OD – optical density.
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validated, as clinically relevant speciﬁc NOX2 inhibitors are not yet
available. Apocynin, an antioxidant molecule with a complex
mechanism of action [10,33] commonly advertised as a NOX in-
hibitor, has been administered to SOD1G93A mice; however, it
failed to improve symptoms [34,35]. In an effort to identify small
molecule NOX inhibitors, we have recently characterized thior-
idazine and other N-substituted phenothiazines as pan-NOX in-
hibitors [12]. Although phenothiazines have numerous modes of
action in the CNS, they represent an interesting tool for target
validation because their concentration in the CNS upon i.p. injec-
tion is compatible with NOX inhibition. In addition, perphenazine
and thioridazine are already approved for human use allowing
potential straightforward repositioning of these compounds into a
clinical trial for ALS.
In a ﬁrst set of experiments, we veriﬁed the induction of NOX2
expression in the CNS of ALS mice in three etiologically differentdisease models. This ﬁnding is compatible with involvement of
NOX2 in a common pathomechanism for ALS and possibly other
neurodegenerative disorders [7]. More detailed investigation in
SOD1G93A mice showed NOX2 up-regulation at both transcrip-
tional and protein levels and identiﬁed a related up-regulation of
the subunits necessary for NOX2 activity. The levels of NOX2 are
also increased in human ALS samples. We observed a typical mi-
croglial staining for NOX2 in human spinal cord, corroborating
previous reports [7,8] and recent RNAseq data showing that NOX2
expression is restricted to microglia in the healthy mouse and
human CNS ([36,37], see also http://web.stanford.edu/group/
barres_lab/brain_rnaseq.html). NOX2 increase in the spinal cord of
ALS mice and patients is most likely due to proliferation and ac-
tivation of microglia although inﬁltration of mononuclear in-
ﬂammatory cells may account at least in part for this increase. It is
indeed difﬁcult to distinguish the respective impact of macro-
phages and parenchymal microglia as they share the same speciﬁc
Fig. 5. In vivo pharmacology of perphenazine and thioridazine. Brain concentrations of compounds were determined upon i.p. injection of (A) perphenazine, 3 mg/kg and
(B) thioridazine, 10 mg/kg. Dotted line shows IC50 value for NOX2 inhibition in Amplex red assay in PLB985 cells [12]. (C-F) LC/MS/MS quantiﬁcation of HE oxidation products
measured in the spinal cord tissue of SOD1G93A mice (females, 110 days) following administration of thioridazine or saline and non-carriers (NC). HE was administered
intraspinally 30 min before collection of spinal cord. The following HE oxidation products were detected and quantiﬁed (C) 2-hydroxyethidium (2-OH-Eþ), the speciﬁc
product of the reaction of HE with O2∙- [30]; (D) ethidium (Eþ) and (E) ethidium dimers (Eþdimer) which are formed by unspeciﬁed oxidants [31] and (F) 2-chlorethidium
(2-Cl-Eþ), a speciﬁc product formed from the reaction of HE with hypochlorous acid (HOCl) [21]. The values are presented as ratio to total HE detected (individual values and
mean). Mann-Whitney test, *po0.05, **po0.01. Thio – thioridazine.
Table 2
Treatment protocol.
Treatment Gender Dosage (mg/
kg/d)
Mean survival (n) Log-rank test,
p valueVehicle Drug
Perphenazine Females 3 137 (30) 140 (31) 0.0838
Thioridazine Females 10 132 (39) 134 (31) 0.3353
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unlikely that the inﬁltration of T-lymphocytes accounts for this
increase since the expression of NOX2 in T-cells is very low (if any)
[38].
In contrast, based on the RNAseq data cited above, the presence
of NOX4 in spinal cord homogenates might be due to its en-
dothelial expression. The low level expression of NOX1 is likely
due to vascular smooth muscle cells; however, the marked NOX3
Fig. 6. Effect of perphenazine treatment on survival, weight and motor function of SOD1G93A mice. Female SOD1G93A mice were treated with perphenazine (3 mg/kg/day i.p).
starting from day 70 until the end stage. (A) Survival: Log-rank (Mantel-Cox) Test shows no signiﬁcant differences in survival of mice treated with perphenazine (n¼31) as
compared to vehicle treated mice (n¼30). (B) Body weight: slight improvement in body weight loss was detected in perphenazine treated mice as compared to vehicle
treated mice (n¼42 per group up to 110 days, n¼30 per group until the terminal stage), t-test performed for each time point to compare treatment versus vehicle, *po0.05;
**po0.005. (C) Rotarod: no improvement in motor function was detected (n¼24 vehicle; n¼25 perphenazine). (D) Grid test: no improvement of motor function was
observed in this test, n¼31 per group. Traces from historical control NC littermates are shown in (A - C) as grey dotted line (n¼12).
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ticipated since NOX3 expression is almost completely restricted to
the inner ear and to embryonic tissue. Unfortunately, the lack of
validated mouse NOX3 antibodies is a limitation to identify the
speciﬁc cellular localization of NOX3 in the spinal cord of ALS
mice. Another interesting observation is that DUOXA1 is expressed
in the spinal cord tissue and upregulated with the course of the
disease. DUOXA1 is known as a subunit necessary for the activity
of DUOX1. However DUOX1 was below detection levels in the
analyzed tissues. This suggests a possible role for DUOXA1 in the
CNS which is independent of DUOX1.
Importantly, the increase in the expression of NOX enzymes
was accompanied by an increase of ROS in the spinal cord in vivo.
We used LC/MS/MS analysis of HE and its oxidation products as,
unlike the standard ﬂuorescence detection of HE oxidation, it al-
lows for the detection and quantiﬁcation of speciﬁc products of HE
oxidation, including those with O2∙ and hypochlorous acid, the
latter usually produced by MPO in activated neutrophils. This
method indicated that general oxidation is increased in the spinal
cord of SOD1G93A mice, but also that the increased levels of O2∙ ,
the speciﬁc primary product of NOX, were decreased in thior-
idazine-treated animals, compatible with the notion that NOX is
inhibited in vivo. Conversely, the levels of chlorinated HE, the
product of MPO activity, were unchanged. The absence of MPO
activity likely reﬂects the absence of neutrophil inﬁltration in the
spinal cord of ALS mice. Interestingly, the increase in ROS mea-
sured in spinal cord (1.5-fold) appears substantially lower than the
induction of NOX2 mRNA (420-fold) in ALS spinal cord. This maysuggest that although NOX2 is present, it may not be fully acti-
vated. The expression of regulatory subunits (p47phox, p67phox and
p40phox) shows 2–5 fold increase. This might limit NOX2-derived
superoxide generation since the active complex requires equimo-
lar assembly of all subunits. In addition NOX2 requires activation
for the generation of ROS. This is illustrated by ROS measurements
in microglial cells: increased NOX2 expression upon LPS pre-
treatment is not sufﬁcient to generate ROS and requires additional
stimulation with PMA, a PKC activator. In addition to NOX, other
sources of ROS, including mitochondria, xanthine oxidase, cyto-
chrome P450 or iNOS, may be relevant sources of oxidative stress
in ALS and other neuroinﬂammatory conditions [39–41]. It is
possible that thioridazine interferes with one or several of these
systems [42,43].
Despite strong up-regulation of the NOX2 complex in SOD1G93A
mice, associated with increased O2∙ in vivo, which can be miti-
gated by thioridazine treatment, we found no improvement in
survival following pharmacological intervention with thioridazine
or perphenazine. A possible explanation for the lack of impact on
survival of the N-substituted phenothiazine treatment is their in-
sufﬁcient CNS exposure. Although the concentrations of perphe-
nazine and thioridazine in the CNS were above or higher than the
IC50 for NOX2 inhibition for at least 8 h, we cannot exclude that
CNS exposure obtained upon a single injection of the drug was not
sufﬁcient in a 24 h period. We selected a single daily dose in order
to avoid long period of drowsiness in mice induced by high doses
of phenothiazines. Another possible explanation is that NOX in-
hibition alone is insufﬁcient to slow down disease progression and
Fig. 7. Effect of thioridazine treatment on survival, weight and motor function of SOD1G93A mice. Female SOD1G93A mice were treated with thioridazine (10 mg/kg/day i.p).
starting from day 70 until the end stage. (A) Survival: Log-rank (Mantel-Cox) Test shows no signiﬁcant differences in survival of mice treated with thioridazine (n¼31) as
compared to vehicle treated mice (n¼39). (B) Body weight: no improvement was detected in thioridazine treated mice (n¼30) as compared to vehicle treated mice (n¼30).
(C) Rotarod: improvement of motor function was detected at the early symptomatic stage of the disease (Two way ANOVA followed by Bonferroni multiple comparisons test,
n¼30 per group); no differences between groups were observed at the later stages of disease. (D) Grid test: no improvement of motor function was observed in this test,
n¼30 per group. Traces from historical control NC littermates are shown in (A - C) as grey dotted line (n¼12).
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and NOX2-deﬁcient mice did not impact the survival or motor
neuron loss. Our results are in disagreement with previous studies,
which reported increased survival of 13 days [8] and 97 days [32]
of ALS mice cross-bred with NOX2-deﬁcient mice and 33 days for
NOX1 genetic ablation [32]. The discrepancy with the ﬁrst report
(13 days) is most likely due to genetic background effect. SOD1G93A
mice used in this study are in the hybrid B6/SJL background while
NOX2-deﬁcient mice are in the B6 background. The survival of
mice with SOD1G93A mutation is increased when the transgene is
carried in a pure B6 background [25]. We similarly observed an
increased survival of 12 days in males in the mixed background
compared to the hybrid background for both breeding with NOX2
and NOX1-deﬁcient mice. The massive survival effect of NOX2
(and to a less extent NOX1) deletion reported by others [32] could
not be reproduced. In our study, we followed speciﬁc standard
operating procedures for pharmacological treatments [44] and
used non-carrier littermates as control for evaluation of survival.
Inducible genetic ablation of NOX2 speciﬁcally in microglia would
provide a further insight into its contribution to the progression of
ALS.
Although chronic administration of perphenazine or thior-
idazine failed to improve the survival of ALS mice, both molecules
modiﬁed speciﬁc molecular markers and clinical symptoms in thismodel. Undeniably, in addition to NOX inhibitory activity, per-
phenazine and thioridazine have multiple actions in the CNS, such
as D2 dopamine receptor antagonism, among others (reviewed in
[45,46]). Strikingly, despite high structural similarities, the two
N-substituted phenothiazines tested in this study had opposite
effects on glial markers. Perphenazine treatment showed an in-
crease of the expression of NOX2 and CD68 and a trend to an in-
crease of GFAP and Iba1, while thioridazine treatment had the
opposite effect. The reason for this difference is unclear, however
we cannot exclude that the less favorable pharmacokinetics proﬁle
of perphenazine is involved. Besides, different aspects of disease
progression were affected by the two treatments. Perphenazine
slowed down the weight loss of SOD1G93A mice, which could be
explained by the known weigh gain promoting effect of anti-
psychotics [47]. Thioridazine treatment resulted in an immediate
enhancement of rotarod performance to the level of controls
during early disease stages (day 70–day 100). This is a potentially
interesting ﬁnding; however it is not clear whether this effect is
due to NOX inhibition.
5. Conclusion
In this study, we demonstrate that the expression of NOX2
isoform of the NADPH oxidase family is strongly increased in the
Fig. 8. Analysis of neuronal and glial markers expression in spinal cord of SOD1G93A mice treated with perphenazine or thioridazine. (A) mRNA levels of NOX2 and its subunit
p47phox and neuronal (NEFL), microglial (Iba1, CD68) and astrocyte (GFAP) markers were assessed using qPCR in the spinal cord of (A) SOD1G93A mice aged 110–115 days
treated with perphenazine (n¼7) or thioridazine (n¼6) and compared to vehicle-treated mice (n¼7) and SOD1G93A non-carrier mice (NC) (n¼6), Expression values were
normalized to geometric mean of two house-keeping genes (GAPDH and HPRT) and expressed as a fold-change of SOD1G93A non-carrier mice (NC). Values are presented as
mean7SEM. Mann-Whitney test, *po0.05, **po0.01, ***po0.001. (B) Immunohistochemical analysis of neuronal (Cresyl violet, arrows indicate surviving motor neurons),
microglial (Iba1) and astrocyte (GFAP) markers in lumbar spinal cord of SOD1G93A mice aged 110–115 days. n¼3 per group. Scale bar 25 mM. Images were taken in the area
corresponding to ventral horn. (C) Quantiﬁcation of immunostaining in B.
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and correlates with the level of microgliosis and severity of dis-
ease. As opposed to former studies, constitutive genetic deletion of
NOX1 or NOX2 did not improve survival of ALS mice. Using a novel
LC/MS/MS based method we were able to detect speciﬁc increase
of intraspinal superoxide in ALS mice, which could be mitigated by
thioridazine, a broad spectrum NOX inhibitor. Thioridazine
showed favorable CNS pharmacokinetics and moderate enhance-
ment of motor function without an impact on the later disease
stages and mortality. While thioridazine is an imperfect tool to
study the involvement of NOX in ALS, novel effort for identiﬁcationof NOX2 inhibitors [11] and the recently discovered BBB permeable
speciﬁc NOX2 inhibitor GSK2795039 [10] may represent favorable
approaches for further validation of the therapeutic potential of
NOX inhibition for the treatment of ALS and other neurodegen-
erative diseases.Competing interests
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